by Eric Christianson | Dec 3, 2023 | Endocrine Medication and Disease State Clinical Pearls
Many institutions that pass medications need to be aware of when medications expire. The GLP-1 agonist class has been quickly expanding so we wanted to put together a storage chart to ensure that healthcare professionals and patients properly store their medications....
by Eric Christianson | Nov 29, 2023 | Cardiovascular Medication and Disease State Clinical Pearls
In a discussion of statins and myalgia, it is always important to start with definitions. Muscle-related conditions associated with statins: Myalgia: Muscle pain. Defined as muscle symptoms without significant elevation of creatinine kinase (CK). Myopathy: Disease of...
by Eric Christianson | Nov 19, 2023 | Clinical Pharmacy News and New Drug Updates, Endocrine Medication and Disease State Clinical Pearls
Weight loss has been an essential area in which many pharmaceutical companies have made interventions by providing effective medications that can assist patients dealing with obesity. In this article, we will compare the newly approved weight loss medication Zepbound...
by Eric Christianson | Nov 15, 2023 | Gastrointestinal Medication and Disease State Clinical Pearls
This article is going to compare Wegovy versus Ozempic, two different brand-name medications that share the same active ingredient: semaglutide. Both medications are subcutaneous injections, and both are administered once per week using pen injector devices. The...
by Eric Christianson | Nov 8, 2023 | Hematology and Immunology Medication and Disease State Clinical Pearls
Iron therapy can be life-changing for some anemia patients and help them improve their energy and ultimately, their quality of life. Sometimes anemia isn’t responsive to iron. In this article, I discuss my top reasons why patients don’t respond to iron...
by Eric Christianson | Nov 1, 2023 | Cardiovascular Medication and Disease State Clinical Pearls
Calcium channel blockers (CCBs) are split into two categories, dihydropyridines (DHP), such as amlodipine and nicardipine, and non-dihydropyridines (non-DHP), such as verapamil and diltiazem. While these two drug classes are both CCBs, there are some key similarities...
